Lupin gets US nod to market generic Avapro tablets

Top Stories

»	India’s forex reserves on way to reclaim all-time high of $704.8 billion
»	Centre notifies new rules for GST Appellate Tribunal
»	India’s steel industry poised for global growth, focus on FTAs and self-reliance: Piyush Goyal
»	Sensex, Nifty plunge over 1 per cent amid geopolitical tensions
»	‘India Steel 2025’ to deliver roadmap on capitalising international market

SME Times News Bureau | 17 Oct, 2012
Pharma major Lupin Wednesday said it has got approval from the US Food and Drugs Administration (FDA) to market generic versions of Sanofi Aventis' Avapro tablets, prescribed in the treatment of hypertension and nephropathy in Type-II diabetis.

Lupin in a release said its wholly-owned subsidiary Lupin Pharmaceuticals Inc. has received the FDA nod for its Irbesartan tablets, the generic versions of Sanofi's 75, 150 and 300 mg Avapro tablets.

Lupin, the third largest Indian pharmaceutical company by sales, is the fifth largest and fastest growing generics player in the US. Avapro tablets had annual US sales of approximately USD 400.7 million.

The city-based company is producing and developing a wide range of branded and generic formulations and APIs (active pharmaceutical ingredients). It is a significant player in the asthma, cardiovascular, diabetology and pediatric space and holds global leadership positions in the anti-TB and cephalosporin segment.

In the last fiscal, Lupin's consolidated total income and profit after tax were Rs.70,972 million (USD 1.49 billion) and Rs.8,676 million (USD 182 million) respectively.